Chronic lung infections remain a critical concern in both pediatric and adult populations due to their persistent effects on pulmonary tissue architecture and function (
1). Unlike acute infections, which are transient and self-limiting, chronic infections can provoke prolonged inflammation and tissue remodeling, resulting in long-term consequences (
2). Particularly in juveniles, whose lungs are still undergoing developmental changes, such persistent insults can predispose them to irreversible damage, increasing vulnerability to subsequent respiratory diseases and even malignancy (
3). The respiratory tract, constantly exposed to environmental pathogens and irritants, relies on a finely tuned immune system to mount a defense (
4). However, recurrent infections can overwhelm these mechanisms, shifting the immune response from a protective acute phase to a deleterious chronic state (
4). Chronic lung infections, especially those caused by
Pseudomonas aeruginosa or
Haemophilus influenzae, are known to initiate persistent activation of immune cells, including neutrophils and macrophages, which continuously release pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) (
5,
6). This phenomenon is particularly evident in conditions such as cystic fibrosis or bronchiectasis. Central to this inflammatory process is the nuclear factor-kappa B (NF-κB) pathway, which orchestrates the transcription of various genes involved in inflammation and cell survival (
7). Overactivation of this pathway leads to a pro-inflammatory microenvironment that not only damages tissue but also sets the stage for pathological signaling alterations (
8). If left unregulated, this inflammatory state can shift from an adaptive response to one that promotes oncogenesis by facilitating genetic instability, suppressing apoptosis, and altering normal cellular differentiation (
7,
8). Pharmacological inhibition of NF-κB has been proposed as a promising strategy to dampen chronic inflammation and reduce oncogenic risk.
One of the direct consequences of chronic inflammation is the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS), collectively contributing to oxidative stress (
9). Neutrophils, in particular, generate large amounts of ROS during the respiratory burst aimed at destroying pathogens. However, sustained ROS release can damage lipids, proteins, and nucleic acids within host cells, thereby impairing cellular functions and compromising genomic integrity (
10). In the lung, oxidative stress has been implicated in the pathogenesis of various chronic conditions, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer (
11). The excessive generation of ROS leads to the oxidation of guanine bases in DNA, producing mutagenic lesions such as 8-oxo-2'-deoxyguanosine (8-oxo-dG), which can cause point mutations if not efficiently repaired. Moreover, oxidative stress disrupts mitochondrial integrity, amplifying cellular dysfunction and initiating apoptotic or necrotic pathways (
12). To counteract ROS-induced damage, cells activate the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which upregulates antioxidant defense genes, including heme oxygenase-1 (HO-1) and glutamate-cysteine ligase catalytic (GCLC) subunit (
13). However, in the context of chronic infection, the antioxidant response may be insufficient to counterbalance the overwhelming ROS burden, leading to cumulative damage over time. Therapeutically, Nrf2 activators are under investigation for their potential to restore redox balance in chronic pulmonary diseases. The sustained presence of inflammatory and oxidative mediators creates a microenvironment that favors carcinogenesis. Chronic exposure to cytokines and ROS can lead to the activation of proto-oncogenes (e.g., Myc, Kras) and the inactivation of tumor suppressor genes (e.g., TP53), initiating the early steps of transformation (
14). DNA damage responses become chronically engaged, as evidenced by the accumulation of markers such as γH2AX, indicating double-strand breaks. If repair systems become faulty or overwhelmed, mutations may persist and propagate through successive cell divisions (
15).
Additionally, inflammation-associated pathways, including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), produce metabolites that further exacerbate DNA damage or promote cell proliferation and angiogenesis (
16). For instance, COX-2 overexpression has been linked with poor prognosis in non-small cell lung carcinoma (NSCLC), highlighting its dual role in inflammation and cancer development (
17). This highlights COX-2 inhibitors, such as celecoxib, as potential chemopreventive agents in chronic lung inflammation models. In juvenile models, the susceptibility to these effects may be exacerbated due to the immaturity of immune and antioxidant systems. Studies have shown that young animals exposed to inflammatory stimuli exhibit heightened oxidative damage and impaired resolution capacity compared to adults, suggesting a developmental vulnerability that can predispose them to long-term lung pathologies (
18,
19). Children and adolescents exposed to chronic infections — whether due to genetic conditions, environmental exposures, or immune deficiencies — are particularly at risk. The developing lung is highly dynamic, involving extensive cell proliferation, differentiation, and alveolarization. Any interference with these processes, particularly through inflammatory or oxidative insults, can result in permanent alterations in lung architecture and cellular programming (
20). Despite this known vulnerability, few studies have addressed pharmacological strategies to mitigate infection-driven oncogenic transformation during early lung development. There is a critical need to explore therapeutic interventions that can disrupt the cascade from chronic infection to DNA damage and proto-oncogene activation.